Related Experiment Video
Updated: Jun 24, 2026
06:15
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Advances in meningioma therapy.
Andrew D Norden1, Jan Drappatz, Patrick Y Wen
1Center for Neuro-Oncology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.
Current Neurology and Neuroscience Reports
|April 8, 2009
Summary
Meningiomas, common brain tumors, are often benign but can be aggressive. While surgery and radiation are standard, new molecular therapies show promise for recurrent or high-grade meningiomas.
Area of Science:
- Neuro-oncology
- Neurosurgery
- Radiation Oncology
Background:
- Meningiomas are the most common primary brain tumors in adults, with varying grades of malignancy (WHO I-III).
- Complete surgical resection is curative for benign meningiomas, but high-grade or incompletely resected tumors often require adjuvant therapy.
- Recurrence remains a challenge for high-grade meningiomas despite maximal treatment with surgery and radiation.
Purpose of the Study:
- To review the current treatment landscape for meningiomas.
- To highlight the limitations of existing therapies for aggressive meningiomas.
- To explore emerging molecular and targeted drug therapies for meningioma treatment.
Main Methods:
- Review of existing literature on meningioma treatment modalities.
- Analysis of current therapeutic strategies including surgery, radiotherapy, and chemotherapy.
- Discussion of novel therapeutic targets and agents based on molecular pathogenesis.
Main Results:
- Surgery and radiotherapy are effective for benign and some atypical meningiomas, with limited toxicity.
- High-grade meningiomas exhibit a tendency to recur even after aggressive treatment.
- Chemotherapeutic agents like hydroxyurea have shown marginal efficacy in recurrent meningiomas.
Conclusions:
- While surgery and radiation are mainstays, novel therapeutic approaches are crucial for managing recurrent and high-grade meningiomas.
- Targeted drug therapies, including angiogenesis inhibitors and agents targeting cell signaling pathways, show significant promise.
- Further research into the molecular underpinnings of meningiomas will guide the development of more effective treatments.
